Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2018 | Pages:
93 | Publisher: Grand View Research
Industry: Pharmaceutical | Report Format: Electronic (PDF)
The global sarcoma drugs market size is expected to be valued at USD 1.2 billion by 2023, as per a new report by Grand View Research, Inc., progressing at a CAGR of 8.5% during the forecast period. The growth of the market is largely driven by factors such as new product launches, increasing adoption of novel therapeutics, and growing target population. Sarcomas account for less than 1.0% of all adult cancers. Though sarcomas represent a heterogeneous group of over 50 different histological subtypes, the two major subtypes are soft tissue sarcomas (STS) and bone sarcoma. Approximately, 12,000 patients in the U.S. and 28,000 patients in Europe are diagnosed with STS every year. For over 40 years, mainstay of localized sarcoma treatment included surgical resection followed by neoadjuvant or adjuvant radiation or chemotherapy. However, even after complete surgical resection, about 50.0% of patients with intermediate or high grade sarcoma develop metastatic disease. Introduction of targeted therapy has revolutionized treatment paradigm for sarcoma. Targeted therapies and pipeline breakthroughs will continue to play a pivotal role in the growth of the market throughout the forecast period. Further key findings from the report suggest: • EU5 will remain the second largest market with more than 30% share by 2023. The growth of the segment can be attributed to rising incidence of STS, uptake of targeted therapies, and increasing R&D activities • Eli Lilly's Lartuvo has displaced standard doxorubicin therapy as front-line STS treatment and is anticipated to maintain its prominence in the market over the forecast period • Strong unmet needs within the market present a key opportunity to develop breakthrough first-in-class therapies. Out of 45 drugs in the pipeline for sarcoma, seven are in Phase III, 22 in Phase II, two in Phase I/II trials, and the remaining in Phase I and Pre-clinical trials • The potential role for use of immuno-oncology agents in sarcomas is currently under evaluation in Phase I/II clinical trials • Companies with late-stage pipeline products for sarcoma are likely to enter the market by 2019 and would capture more than 10.0% of the sarcoma market share in 2023 • Drugs with novel targets in early-phase development include Novartis's Afinitor (mTOR inhibitor), Tesaro's Zejula (PARP inhibitor), Amgen's Imlygic (gene therapy), and Pfizer's Crizotinib (ALK and MET tyrosine kinases inhibitor) • Role of VEGF inhibitors and mTOR inhibitors is under evaluation in multiple early phase trials. However, no statistically significant data has been reported till date
Table of Contents
Chapter 1 Research Methodology
1.1. Information procurement
1.2. Information or Data Analysis
1.2.1. Market Formulation & Validation
Chapter 2 Executive Summary
Chapter 3 Disease Primer and Epidemiology
3.1 Disease Primer
3.1.1 Soft Tissue Sarcoma (STS)
3.1.2 Bone Sarcoma
3.1.3 Current Prevalence Rate and Incidence Rate for Seven Major Markets (U.S.,Japan,EU5)
Chapter 4 Global Sarcoma Drugs Market Overview
4.1 Sarcoma Drugs Market Overview
4.1.1 Tyrosine kinase inhibitors (c-KIT, PDGFR, and VEGF inhibitors)
4.1.2 Cell Cycle Inhibitors
4.1.3 mTOR inhibitors
4.2 Market, by Treatment Type
4.3 Market Size and Forecast (2017 - 2023)
4.4 Market Size and Forecast, by Seven Major Markets (2017 - 2023)
4.4.1 U.S. Sales by Treatment Type (2017 - 2023)
4.4.2 U.K. Sales by Treatment Type (2017 - 2023)
4.4.3 Germany Sales by Treatment Type (2017 - 2023)
4.4.4 France Sales by Treatment Type (2017 - 2023)
4.4.5 Italy Sales by Treatment Type (2017 - 2023)
4.4.6 Spain Sales by Treatment Type (2017 - 2023)
4.4.7 Japan Sales by Treatment Type (2017 - 2023)
4.5 Market Share Distribution, by Company (2017 - 2023)
4.6 Market Dynamics and Brand Strategies
4.7 Patent Expiry Analysis
4.8 Sarcoma Drugs Market: Drivers and Restraints
4.8.1 Market Drivers
4.8.2 Market Restraints
4.9 M&A, Deal Landscape (2013-2018 YTD)
4.9.1 Mergers & Acquisitions
4.9.2 Deals Landscape
4.10 Pricing and Reimbursement Scenario
4.11 Sarcoma Sector SWOT
Chapter 5 Sarcoma Drugs Market: Pipeline Intelligence
5.1 Pipeline Landscape
5.1.1 Leading Drugs in Development
5.2 Key R&D Trends
5.2.1 Chemotherapy
5.2.2 Targeted Therapy
5.2.3 Immunotherapy
5.2.3.1 Immuno-oncology agents
5.2.3.2 Cancer Vaccines
5.2.3.3 Gene Therapy
5.3 Pipeline Landscape
5.3.1 Late Stage Pipeline Drugs
5.4 Clinical Profiles of Disruptive Drugs
5.5 Global Pipeline Forecast
Chapter 6 Company Profiles
6.1 Novartis
6.1.1 Company Overview
6.1.2 Product Portfolio
6.1.3 Product Forecast Sales through 2023
6.1.4 Strategic Initiatives
6.1.4.1 Key Company News Flow
6.1.5 Pipeline Analysis and Overview
6.1.6 SWOT
6.2 Pfizer
6.2.1 Company Overview
6.2.2 Product Portfolio
6.2.3 Product Forecast Sales through 2023
6.2.4 Strategic Initiatives
6.2.4.1 Key Company News Flow
6.2.5 Pipeline Analysis and Overview
6.2.6 SWOT
6.3 Eli Lilly
6.3.1 Company Overview
6.3.2 Current Product Portfolio
6.3.3 Product Forecast Sales through 2023
6.3.4 Strategic Initiatives
6.3.4.1 Key Company News Flow
6.3.4.2 Catalysts & Events Calendar
6.3.5 Pipeline Analysis and Overview
6.3.6 SWOT
6.4 Eisai
6.4.1 Company Overview
6.4.2 Product Portfolio
6.4.3 Product Forecast Sales through 2023
6.4.4 Strategic Initiatives
6.4.4.1 Key Company News Flow
6.4.5 Pipeline Analysis and Overview
6.4.6 SWOT
6.5 Johnson & Johnson
6.5.1 Company Overview
6.5.2 Product Portfolio
6.5.3 Product Forecast Sales through 2023
6.5.4 Strategic Initiatives
6.5.4.1 Key Company News Flow
6.5.5 Pipeline Analysis and Overview
6.5.6 SWOT
6.6 Bayer
6.6.1 Company Overview
6.6.2 Product Portfolio
6.6.3 Product Forecast Sales through 2023
6.6.4 Strategic Initiatives
6.6.4.1 Key Company News Flow
6.6.5 Pipeline Analysis and Overview
6.6.6 SWOT
Chapter 7 Market Outlook
7.1. What the Future Holds
7.2. The Winners and Losers
7.2.1. Winners
7.2.2. Losers
7.3. Emerging Companies/New Technology Platforms
7.4. The Road Ahead
List of Tables TABLE 1 Sarcoma - Classification TABLE 2 Soft-Tissue Sarcoma - Staging and Five-Year Survival Rate TABLE 3 Bone Sarcoma - Staging and Five-Year Survival Rate TABLE 4 First-line Chemotherapy for Sarcoma (Generics) TABLE 5 Marketed Drugs for Sarcoma TABLE 6 Sales by Treatment Type, in $ Million, 2017 - 2023 TABLE 7 Sales Performance by Country, in $ Million, 2017 - 2023 TABLE 8 U.S., Sales by Treatment Type (2017 - 2023) TABLE 9 U.K., Sales by Treatment Type (2017 - 2023) TABLE 10 Germany, Sales by Treatment Type (2017 - 2023) TABLE 11 France, Sales by Treatment Type (2017 - 2023) TABLE 12 Italy, Sales by Treatment Type (2017 - 2023) TABLE 13 Spain, Sales by Treatment Type (2017 - 2023) TABLE 14 Japan, Sales by Treatment Type (2017 - 2023) TABLE 15 Patent Expiry Analysis TABLE 16 R&D Pipeline Overview - Leading Drugs TABLE 17 Late Stage Pipeline Analysis TABLE 18 BLU-285 (avapritinib) TABLE 19 INNO-206 (Aldoxorubicin) TABLE 20 TRC105 (carotuximab) TABLE 21 Pipeline Forecast TABLE 22 Novartis Product Forecast Sales (2017 - 2023) TABLE 23 Pfizer Product Forecast Sales (2017 - 2023) TABLE 24 Eli Lilly Product Forecast Sales (2017 - 2023) TABLE 25 Eisai - Product Forecast Sales (2017 - 2023) TABLE 26 Johnson & Johnson Product Forecast Sales (2017 - 2023) TABLE 27 Bayer Product Forecast Sales (2017 - 2023)
List of Figures FIG. 1 Market research process FIG. 2 Information Procurement FIG. 3 Primary research pattern FIG. 4 Market research approaches FIG. 5 Value chain based sizing & forecasting FIG. 6 QFD modelling for market share assessment FIG. 7 Sarcoma Major Subtypes FIG. 8 U.S. - Soft Tissue Sarcoma Incidence and Mortality Trends FIG. 9 U.S. - Bone Sarcoma Incidence and Mortality Trends FIG. 10 U.K.- STS Incidence Rates per 100,000 Population, by Sex FIG. 11 U.K.-Bone Sarcoma Incidence Rates per 100,000 Population, by Sex FIG. 12 Germany- Sarcoma Incidence and Mortality Trends FIG. 13 Germany- Age-Standardized Incidence Rate per 100,000 people FIG. 14 France - STS Age-Standardized Incidence Rate per 100,000 people FIG. 15 Japan - Sarcoma Incidence Trends FIG. 16 Treatment Type, Market Share Distribution, 2017 and 2023 FIG. 17 Regional Market Size, 2017 & 2023 FIG. 18 Market Shares Distribution, by Company (2017 & 2023) FIG. 19 Sarcoma Sector SWOT FIG. 20 Sarcoma R&D Pipeline - Drugs in Development FIG. 21 Sarcoma R&D Pipeline, by Treatment Type FIG. 22 Immunotherapy Types In Development for Sarcoma Treatment FIG. 23 Novartis Sarcoma Sales Forecast FIG. 24 Novartis SWOT Analysis FIG. 25 Pfizer Sarcoma Sales Forecast FIG. 26 Pfizer SWOT Analysis FIG. 27 Eli Lilly Sarcoma Sales Forecast FIG. 28 Eli Lilly SWOT Analysis FIG. 29 Eisai Sarcoma Sales Forecast FIG. 30 Eisai SWOT Analysis FIG. 31 Johnson & Johnson Sarcoma Sales Forecast FIG. 32 Johnson & Johnson SWOT Analysis FIG. 33 Bayer Sarcoma Sales Forecast FIG. 34 Bayer SWOT Analysis
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
